Celularity Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CELU Nasdaq 2836 www.celularity.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celularity Inc.

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies - Jun 4th, 2026 6:00 am
Celularity Releases CEO Letter to Shareholders - Jun 3rd, 2026 2:15 pm
Celularity Appoints Rick Gonzalez as Chief Commercial Officer - Jun 3rd, 2026 6:00 am
Celularity Receives Nasdaq Notice Regarding Form 10-Q - May 29th, 2026 3:15 pm
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors - May 6th, 2026 7:00 am
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - May 1st, 2026 2:30 pm
NEXGEL Appoints Ian Blackman as Chief Financial Officer - Apr 27th, 2026 7:00 am
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - Apr 21st, 2026 7:00 am
Celularity Announces Closing of Transaction with NexGel - Apr 21st, 2026 6:30 am
NEXGEL, Inc. Q4 2025 Earnings Call Summary - Apr 21st, 2026 6:30 am
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - Apr 17th, 2026 2:35 pm
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction - Apr 15th, 2026 2:12 pm
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction - Apr 8th, 2026 2:05 pm
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity - Mar 31st, 2026 2:12 pm
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products - Mar 12th, 2026 6:45 am
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - Mar 12th, 2026 6:30 am
Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board - Mar 12th, 2026 1:33 am
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products - Mar 10th, 2026 6:45 am
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy - Mar 10th, 2026 6:30 am
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses - Feb 10th, 2026 6:30 am